Chagas Disease Drug Market Analysis - Global Industry Size, Share, Trends and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC687


Chagas disease is tropical parasitic disease caused by trypanosoma cruzi. Chagas disease is transferred by triatomine bugs or kissing bugs. Chagas disease can also spread through mother to fetus during pregnancy, blood transfusions, and sometimes from organ transplantation. The symptoms of this disease in early stage are headache, fever, swollen lymph nodes, and others. The chronic symptom appears after 8-12 weeks including enlargement of ventricles indicating to the heart failure causing death. Hence, growing awareness for this disease may boost chagas disease drug market growth in near future. 

Market Dynamics

Increasing population suffering from chagas disease and increase in research and development (R&D) of innovative products are some of the key drivers for this market growth. Conversely, lack of awareness for treatment, limited approved products in present market, and supply chain problems associated to chagas disease drugs will restraint growth of this market in near future. Rising incidences of chagas disease owing to unhygienic surroundings is expected to boost the growth of this market.

Market Classification

The market can be bifurcated on the basis of drug type, treatment type, distribution channel, and geography. By drug type, chagas disease drug market can be segmented into benznidazole, nifurtimox and others. By treatment type, chagas disease drug market can be segmented into antiparasitic treatment and symptomatic treatment. By distribution channel, chagas disease drug market can be segmented into hospital pharmacies, online pharmacies and retail pharmacies. On the basis of geography, the chagas disease drug market can be segmented into North America, Latin America, Europe, Middle East & Africa (MEA) and Asia-Pacific.

Report Coverage


Chagas Disease Drug Market

Analysis Period

2015 – 2026

Historic Data

2015 – 2016

Base Year


Forecast Data

2018 – 2026

Market Stratification

Drug Type, Treatment Type, Distribution Channel, Geography

Regional Scope

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA)

Report Coverage

Market Trends, Drivers, Restraints, Porter's Five Forces Analysis, Competitive Analysis,

Player Profiling, Value Chain Analysis


Market Participants

Some of the major players involved in chagas disease drug market include AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co Ltd, Eisai Co Ltd, GlaxoSmithKline Plc, Grupo Praxis Pharmaceutical SA, Humanigen Inc, Kancera AB, Merck & Co Inc, Novartis AG, Oblita Therapeutics BVBA, and Sanofi SA among others.

Market Segmentation

Market By Drug Type

  • Benznidazole
  • Nifurtimox
  • Others

Market By Treatment Type

  • Antiparasitic Treatment
  • Symptomatic Treatment

Market By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of LATAM
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Cart Summary